Alpha Cognition (ACOG) announced that the United States Patent and Trademark Office has granted a new patent titled “Coated Tablets for pH-Dependent Release of Benzgalantamine.” This newly issued patent strengthens Alpha Cognition’s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the company’s existing patent protections. With this approval, Zunveyl has patent protection in the United States through 2044, supporting the company’s long-term growth strategy as it prepares for commercialization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACOG:
- Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
- Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
- Alpha Cognition files to sell 1.45M common shares for holders
- Alpha Cognition Raises $52.8 Million in Stock Offering
- Alpha Cognition Reports Promising Data for Brain Injury Drug